Topics:

Atrial Fibrillation

Atrial Fibrillation

Results of the LEGACY study show long-term weight loss decreases AF burden and supports sustained sinus rhythm. A short slide show summarizes the 2015 ACC late-breaking abstract.

What does the patient with atrial fibrillation who would benefit from oral anticoagulation look like today? Q & A, here.

A small study highlights a big point: manage risk factors that affect the atrial fibrillation substrate and ablation therapy success rates improve (ARREST-AF Cohort Study).

CHA2DS2-VASc scoring system

What is your command of the components of this risk prediction tool for patients with atrial fibrillation? Find out with our 4-question quiz.

Rhythm control in atrial fibrillation

When is a rhythm control strategy appropriate? Which patients are candidates for amiodarone? When is AF ablation the answer? Here, a top-line review of rhythm control for atrial fibrillation.

Edoxaban, NOAC antidote

The absence of an antidote may soon disappear as a reason to avoid prescribing a novel oral anticoagulant to patients with atrial fibrillation, based on promising phase III trial results.

The risk for major bleeding and GI hemorrhage in patients taking dabigatran was greater than in those taking warfarin; warfarin, however, was associated with a greater risk of intracranial hemorrhage.

Pages

Subscribe to Atrial Fibrillation on [sitename]

CME Center

Earn CME Credits for reading Psychiatric Times articles. Click here to go to our free online CME activities.

By clicking Accept, you agree to become a member of the UBM Medica Community.